Drug Profile
Research programme: phytochemical-based therapeutics - Neuropathix
Alternative Names: Plant extracts-based therapeutics - NeuropathixLatest Information Update: 24 Nov 2020
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Neuropathix
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain injuries; Hepatic encephalopathy
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for research development in Brain injuries in USA
- 28 Jan 2019 No recent reports of development identified for research development in Hepatic-encephalopathy in USA
- 20 Dec 2013 Early research in Brain injuries in USA (unspecified route)